A Randomized multicenter double blind Phase III study of Nivolumab or placebo in subjects with resected esophageal junction cancer.
Clinical Trial Grant
Awarded By
Bristol-Myers Squibb Company
Start Date
July 1, 2016
End Date
May 10, 2025
Awarded By
Bristol-Myers Squibb Company
Start Date
July 1, 2016
End Date
May 10, 2025